Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
A roundtable discussion on February 10, 2023 between the German Society for Allergology and Clinical Immunology (DGAKI) and the Paul-Ehrlich-Institut (PEI) aimed to discuss in detail current aspects of allergen immunotherapy (AIT), its regulatory framework under the transitional provision of the Therapy Allergen Ordinance (TAO), and the consequences for the planned guideline work of the DGAKI, regulatory challenges in the approval of AIT products for children and adolescents as well as allergy diagnostics. The content and discussion points of this dialogue are summarized and are set in context with the current literature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10740146 | PMC |
| http://dx.doi.org/10.5414/ALX02450E | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Changes in House Dust Mite Component Specific Immunoglobulin Levels Predict the One-Year Efficacy of Allergen Immunotherapy in Patients With Allergic Rhinitis.
Clin Transl Allergy
September 2025
Department of Otolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.
Background: The efficacy of subcutaneous immunotherapy (SCIT) in allergic rhinitis (AR) patients varies. Component-resolved diagnostics (CRD) may serve as a useful tool to predict therapeutic responses.
Methods: Forty-three house dust mite (HDM)-sensitized AR patients undergoing SCIT were enrolled.
Can immunotherapy prevent the progression of airway disease?
Curr Opin Allergy Clin Immunol
August 2025
Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
Purpose Of Review: The potential of allergen immunotherapy (AIT) to prevent allergic airway disease progression are demonstrated. Though not all patients benefit equally, there is limited research on which patients may benefit most.In this article, we focus on factors that may influence the risk of progression and their influence on the preventive effects of AIT, and whether some patients may benefit more than others may.
View Article and Find Full Text PDFSystematic Review and Meta-Analysis of Oral Immunotherapy Effect on Food Allergy-Related Quality of Life.
Allergy
September 2025
Allergy Immunology, Murdoch Children's Research Institute, Parkville, Australia.
Background: Uncertainty exists regarding the health-related quality of life (HRQL) benefits of food allergen oral immunotherapy (OIT). Up-to-date meta-analyses incorporating HRQL data from recent randomised trials are lacking.
Methods: Systematic searches of MEDLINE, Embase, CENTRAL and Google Scholar were conducted for food OIT randomised trials (versus any comparator) that measured HRQL with a validated instrument (27 July 2023).
Multiomics approach to evaluating personalized biomarkers of allergen immunotherapy.
J Allergy Clin Immunol
September 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom; Frankland and Kay Allergy Centre, UK NIHR Imperial Biomedical Research Centre, United Kingdom.
Recent advancements in genomics and "omic" technologies have ushered in a transformative era referred to as personalized or precision medicine. This innovative approach considers the unique genetic profiles of individuals, along with a range of variability factors, to devise tailored disease treatments and prevention strategies that cater to the distinct needs of each patient. Although the terms personalized medicine and precision medicine are frequently utilized interchangeably, it is essential to delineate the subtle distinctions between them.
View Article and Find Full Text PDFRecombinant Allergy Vaccine-Induced Transmission of Maternal Allergen-Specific Neutralizing IgG.
Allergy
September 2025
National Research Center, Institute of Immunology FMBA of Russia, Moscow, Russian Federation.